A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
← catalyst calendarNCT06797869 · readout in 1 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
142actual
Sites
54
Countries
Canada, Denmark, France +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-29 | actual | When the study began enrolling |
| Primary completion | 2026-08-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-21 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diabetes Mellitus, Type 2
- Diabetic Peripheral Neuropathy
Interventions
- Drug: CagriSema (Cagrilintide B and Semaglutide I)
- Drug: Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Primary outcome
what the primary-completion date above is the date OFChange in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS)
measured From baseline (week 0) to end of treatment (week 32)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed